Micrometastases in a murine lung carcinoma model have regressed or been prevented (pages 1179–1183).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mandelboim, O. et al. Regression of established murine carcinoma metastases following vaccination with tumor associated antigen peptides. Nature Med. 1, 1179–1183 (1995).
Boon, T., Certottini, J., van den Eynde, B., van der Bruggen, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immun. 12, 337–365 (1994).
Nanda, N. & Sercarz, E. Induction of anti-self-immunity to cure cancer. Cell 82, 13–17 (1995).
Moller, G. Tumor immunology. Immunol. Rev. 145, 5–250 (1995).
Mandelboim, O. et al. CTL induction by a tumour associated antigen octapeptide derived from a murine lung carcinoma. Nature 369, 67–71 (1994).
Cox, A. et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T Cell lines. Science 264, 716–719 (1994).
Castelli, C. et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphcytes. J. exp. Med. 181, 363–368 (1995).
Van den Eynde, B. . et al. A new family of genes coding for an antigen recognized by autologus cytolytic T lymphocytes on a human melanoma. J. exp. Med. 182, 689–698 (1995).
Wolfel, T. et al. Ap16-INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).
Ressing, M. et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immun. 154, 5934–5943 (1995).
Krensky, A., Reiss, C., Mier, J., Strominger, J., Burakoff, S. Long-term human cytolytic T-Cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc. natn. Acad. Sci. USA. 79, 2365–2369 (1982).
Monach, P., Meredith, S., Siegel, C. & Schreiber, H. A unique tumor antigen produced by a single amino acid substitution. Immunity 2, 45–49 (1995).
Melief, C. & Kast, M. T-Cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 146, 167–177 (1995).
Feltkamp, M. et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type16-induced tumors. Eur. J. Immunol. 25, 2638–2642 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Strominger, J. Peptide vaccination against cancer?. Nat Med 1, 1140 (1995). https://doi.org/10.1038/nm1195-1140
Published:
Issue date:
DOI: https://doi.org/10.1038/nm1195-1140
